GEN Exclusives

More »

GEN News Highlights

More »
Jul 22, 2013

Astellas: FDA OKs Kidney Transplant Rejection Drug

  • Astellas Pharma announced it has received FDA approval for Astragraf XL™ (tacrolimus extended-release capsules) for the prophylaxis of kidney rejection in patients receiving a transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction.

    The firm said its Astragraf XL is the first once-daily oral tacrolimus formulation available to kidney transplant recipients in the U.S. As part of an immunosuppressive regimen for the prophylaxis of organ rejection, “Astragraf XL offers a potentially promising treatment option for appropriate kidney transplant recipients,” Astellas said.

    FDA’s approval stemmed from a review of results of two primary, randomized, comparative Phase III studied involving more than 1,000 patients in the U.S., Europe, Canada, South America, Australia, and South Africa. Astellas added that its drug earned marketing approval under the name Advagraf® in Europe in 2007, and a year later in Japan, under the name Graceptor®.

    "Each transplant recipient is different and requires a personalized treatment approach. The approval of ASTAGRAF XL marks an important milestone in post-transplant care as it provides physicians with a new treatment option for kidney transplant recipients," Astellas Pharma CMO Sef Kurstjens, M.D., PhD., said in a statement.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »